3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
20
Lung Neoplasms
10
Small Cell Lung Carcinoma
6
Neoplasms
5
Carcinoma, Hepatocellular
5
Carcinoma
4
Urinary Bladder Neoplasms
3
Pancreatic Neoplasms
3
Neoplasms by Site
3
Neoplasm Metastasis
3
Endometrial Neoplasms
3
Cholangiocarcinoma
3
Neoplasms by Histologic Type
2
Liver Neoplasms
2
Gallbladder Neoplasms
2
Biliary Tract Neoplasms
2
Bile Duct Neoplasms
2
Vaccinia
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Resectable Intrahepatic Cholangiocarcinoma
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oropharyngeal Neoplasms
1
Non-Small Cell Lung Cancer Metastatic
1
Non-Muscle Invasive Bladder Neoplasms
1
Interventions
enzalutamide
21
Magnetic Resonance Spectroscopy
21
apalutamide
17
Androgen Antagonists
14
Specimen Handling
13
Prednisone
13
Abiraterone Acetate
13
abiraterone
9
Docetaxel
9
Radiotherapy
8
Biopsy
8
darolutamide
7
Radiosurgery
7
Pluvicto
7
Nivolumab
7
cabazitaxel
6
Lutetium-177
6
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
6
Lutetium
5
radium Ra 223 dichloride
4
pembrolizumab
4
niraparib
4
gallium 68 PSMA-11
4
cabozantinib
4
bicalutamide
4
atezolizumab
4
Watchful Waiting
4
Surveys and Questionnaires
4
Standard of Care
4
Radiotherapy, Intensity-Modulated
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
durvalumab
×
30 days
×
Clear all
No trials found.